A Phase 2 interventional study of Apremilast (CC-10004) and Placebo in Behcet Syndrome, sponsored by Amgen. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-19.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Behcet Syndrome with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Behcet Syndrome · United States.
Among the 26 studies in Behcet Syndrome with a site in United States, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2009, is one of 5 in phase 2, and was the 4th registered.
136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.
Browse Behcet Syndrome studies →6 of the 26 studies in Behcet Syndrome with a site in United States are open now. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 5–85 · Healthy volunteers
Chugai Pharmaceutical · Sites in United States, Australia, Austria and 17 more countries
Ages 18–85
Sanguine Biosciences · Sites in United States
Ages 18–85 · Healthy volunteers
Yale University · Sites in United States
Ages 18–99 · Healthy volunteers
University of Pennsylvania · Sites in United States
Ages 18–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 3 · Phase 4 1
First in 1999; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 50 across 70 interventional studies indexed under Behcet Syndrome.
Median enrollment 60 across the 13 interventional studies, 386 across the 13 observational. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 26 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 4 studies filed under Behcet Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Behcet Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Behcet Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Apremilast (CC-10004)
Drug: Placebo
Treatment Phase Days 1-7: Titration from 10 mg BID apremilast tablets arm A (or matching placebo arm B) to 30 mg BID apremilast arm A(or matching placebo arm B) Day 8-84: Maintenance of 30 mg BID apremilast arm A (or matching placebo arm B) Dose reductions to 20 mg BID apremilast arm A (or matching placebo arm B) are permitted. Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast. Day 92-169: Maintenance of 30 mg BID apremilast arm A or dose reductions to 20 mg BID apremilast arm A (if not previously down titrated)
Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted. Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast. Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)
Number of Oral Ulcers at Day 85
The number of oral ulcers were counted at each visit and at the end of the treatment period (starting point was at baseline).
Time frame: Day 85
Pain of Oral Ulcers as Measured by Visual Analog Scale (VAS) at Day 85
A 100-mm VAS pain scale for oral ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
Time frame: Day 85
Pain of Genital Ulcers as Measured by Visual Analog Scale (VAS) Scores at Day 85
A 100-mm VAS pain scale for genital ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
Time frame: Baseline to Day 85
Area Under the Curve (AUC) for the Number of Oral Ulcers From Day 1 to 85
Area under curve (AUC\^85) from Day 1 to Day 85 for the number of oral ulcers per day was determined using the trapezoidal rule and divided by the days between the date of the last observation and baseline. The AUC was determined using the LOCF approach to impute missing values.
Time frame: Day 1 to Day 85
Area Under the Curve for the Number of Genital Ulcers From Day 1 to 85
Area under curve (AUC\^85) from Day 1 to Day 85 for the number of genital ulcers per day was not analyzed.
Time frame: Day 1 to Day 85
Area Under the Curve (AUC) for the Number of Oral Plus Genital Ulcers From Day 1 to 85
Area under curve (AUC) from Day 1 to Day 85 (AUC\^85) for the number of oral plus genital ulcers per day was determined using the trapezoidal rule and divided by the days between the date of the last observation and baseline. The AUC was determined using the LOCF approach to impute missing values.
Time frame: Day 1 to Day 85
Sum of the Number Oral Ulcers, Genital Ulcers or Oral Plus Genital Ulcers at Day 85
Sum of the number oral ulcers, genital ulcers or oral plus genital ulcers at Day 85
Time frame: Day 85
Percentage of Participants Who Were Oral Ulcer-free (Complete Response), or Whose Oral Ulcers Were Reduced by ≥ 50%, (Partial Response)
Comparison of the percentage of participants who were oral ulcer-free (complete response: free from active oral ulcers), or whose oral ulcers were reduced by ≥ 50%, (partial response) between the apremilast-treated and the placebo-treated groups. In this case, partial response also includes complete response.
Time frame: Baseline and Day 85
Change From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 85
The Behçet's Disease Current Activity Index consists of three component scores, a participant's perception of disease activity, a clinician's overall perception of disease activity and a Behçet's Disease Current Activity Index Score. The score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening) and a negative change from baseline indicates improvement.
Time frame: Day 1 to Day 85 or to early termination visit
Number of Treatment Emergent Adverse Events (TEAE) During the Placebo Controlled Treatment Phase
A Treatment Emergent Adverse Event (TEAE) was defined as any AE occurring or worsening on or after the first treatment of any study drug, and within 28 days after the last dose of the last study drug. A treatment related toxicity was considered by the investigator to be not suspected or suspected. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE.
Time frame: Day 1 to Day 85; maximum exposure to study drug was 13 weeks during treatment phase
Number of New Manifestations of Behçet's Disease or Flare During the Placebo Controlled Treatment Phase
A flare was defined as the development of new manifestations of BD or worsening of existing disease, meeting the following criteria: 1. Organ involvement: any major organ involvement (eg, central nervous system, gastrointestinal tract); 2. Oral/genital ulcers: ≥ 100% increase in the number of oral or genital ulcers from Day 1 or a minimum increase of 3 in the number of oral or genital ulcers, whichever is greater; 3. Arthritis: ≥ 50% increase in the number of swollen joints, or a minimum increase of 3 swollen joints, whichever is greater; 4. Skin lesions (non-oral/genital ulcers): ≥ 50% increase in the total score of the Physician's Global Assessment of Skin Lesions, or a minimum increase of 2 in the total score of the Physician's Global Assessment of Skin Lesions, whichever is greater' 5. New onset or worsening of existing Behçet Disease-related inflammatory eye disease requiring initiation of immunosuppressive therapy (uveitis).
Time frame: Day 1 to Day 85
Number of Oral Ulcers at Day 169
The number of oral ulcers were counted at Day 169 in reference to the participants' first day of active treatment (Day 1 or Day 85).
Time frame: Day 169
Pain of Oral Ulcers as Measured by VAS (VAS Score) at Day 169
A 100-mm VAS pain scale for oral ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
Time frame: Day 169
Pain of Genital Ulcers as Measured by Visual Analog Scale (VAS) at Day 169
A 100-mm VAS pain scale for genital ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
Time frame: Day 1 to Day 169
Behçet's Disease (BD) Current Activity Index Form Score at Day 169
The Behçet's Disease Current Activity Index consists of three component scores, a participant's perception of disease activity, a clinician's overall perception of disease activity and a Behçet's Disease Current Activity Index Score. The score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening) and a negative change from baseline indicates improvement.
Time frame: Day 169
Number of New Manifestations of Behçet's Disease or Flare That Were Not Present at Day 1
A flare was defined as the development of new manifestations of BD or worsening of existing disease, meeting the following criteria: 1. Organ involvement: any major organ involvement (eg, central nervous system, gastrointestinal tract); 2. Oral/genital ulcers: ≥ 100% increase in the number of oral or genital ulcers from Day 1 or a minimum increase of 3 in the number of oral or genital ulcers, whichever is greater; 3. Arthritis: ≥ 50% increase in the number of swollen joints, or a minimum increase of 3 swollen joints, whichever is greater; 4. Skin lesions (non-oral/genital ulcers): ≥ 50% increase in the total score of the Physician's Global Assessment of Skin Lesions, or a minimum increase of 2 in the total score of the Physician's Global Assessment of Skin Lesions, whichever is greater; 5. New onset or worsening of existing Behçet Disease-related inflammatory eye disease requiring initiation of immunosuppressive therapy (uveitis).
Time frame: Day 1 to Day 169
Number of Oral Ulcers at Day 197
The number of oral ulcers were counted at each visit and at the end of the treatment period (starting point was at baseline).
Time frame: Day 197
Pain of Oral Ulcers as Measured by VAS (VAS Score) at Day 197
A 100-mm VAS pain scale for oral ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
Time frame: Day 197
Pain of Genital Ulcers as Measured by Visual Analog Scale (VAS) at Day 197
A 100-mm VAS pain scale for genital ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
Time frame: Day 1 to Day 197
Change From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 197
The Behçet's Disease Current Activity Index consists of three component scores, a participant's perception of disease activity, a clinician's overall perception of disease activity and a Behçet's Disease Current Activity Index Score. The score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening) and a negative change from baseline indicates improvement.
Time frame: Day 1 to Day 197
Summary of Treatment Emergent Adverse Events During the Active Treatment-Extension Phase
A Treatment Emergent Adverse Event (TEAE) is as any AE occurring or worsening on or after the first treatment of any study drug, and within 28 days after the last dose of the last study drug. A treatment related toxicity was considered by the investigator to be not suspected or suspected. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE.
Time frame: Day 1 to Day 197; maximum exposure was 25.1 weeks
Percentage of Participants Who Were Genital Ulcer-free (Complete Response) at Day 85
The percentage of participants who were genital ulcer-free (complete response: free from active genital ulcers)
Time frame: Baseline to Day 85
Percentage of Participants Who Were Genital Ulcer-free (Complete Response) at Day 169
The percentage of participants who were genital ulcer-free (complete response: free from active genital ulcers)
Time frame: Day 1 to Day 169
Percentage of Participants Who Were Genital Ulcer-free (Complete Response)
The percentage of participants who were genital ulcer-free (complete response: free from active genital ulcers)
Time frame: Day 1 to Day 197
The study was conducted at 3 study sites in Turkey and 3 sites in the United States. The first participant enrolled was enrolled on October 23, 2009 and the last participant enrolled was enrolled on May 08, 2012.
| Milestone | Placebo (Oral) BID | Apremilast 30mg (Oral) BID | Placebo/Apremilast 30 mg | Apremilast 30mg/Apremilast 30mg |
|---|---|---|---|---|
| Started | 56 | 55 | 0 | 0 |
| Completed | 45 | 50 | 0 | 0 |
| Not completed | 11 | 5 | 0 | 0 |
| Withdrew: Adverse event | 5 | 4 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 |
| Milestone | Placebo (Oral) BID | Apremilast 30mg (Oral) BID | Placebo/Apremilast 30 mg | Apremilast 30mg/Apremilast 30mg |
|---|---|---|---|---|
| Started | 0 | 0 | 45 | 50 |
| Completed | 0 | 0 | 44 | 47 |
| Not completed | 0 | 0 | 1 | 3 |
| Withdrew: Adverse event | 0 | 0 | 1 | 3 |
| Milestone | Placebo (Oral) BID | Apremilast 30mg (Oral) BID | Placebo/Apremilast 30 mg | Apremilast 30mg/Apremilast 30mg |
|---|---|---|---|---|
| Started | 0 | 0 | 54 | 54 |
| Completed | 0 | 0 | 54 | 54 |
| Not completed | 0 | 0 | 0 | 0 |
The number of oral ulcers were counted at each visit and at the end of the treatment period (starting point was at baseline).
| ulcers/participants | Placebo (Oral) BID | Apremilast 30mg (Oral) BID |
|---|---|---|
| Number of Oral Ulcers at Day 85 | 2.0 ± 0.28 | 0.4 ± 0.28 |
A 100-mm VAS pain scale for oral ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
| units on a scale | Placebo (Oral) BID | Apremilast 30mg (Oral) BID |
|---|---|---|
| Pain of Oral Ulcers as Measured by Visual Analog Scale (VAS) at Day 85 | 36.7 ± 3.23 | 9.9 ± 3.30 |
The percentage of participants who were genital ulcer-free (complete response: free from active genital ulcers)
| percentage of participants | Placebo (Oral) BID | Apremilast 30mg (Oral) BID |
|---|---|---|
| Percentage of Participants Who Were Genital Ulcer-free (Complete Response) at Day 85 | 50 | 100 |
A 100-mm VAS pain scale for genital ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
No measurements were reported for this outcome.
Area under curve (AUC\^85) from Day 1 to Day 85 for the number of oral ulcers per day was determined using the trapezoidal rule and divided by the days between the date of the last observation and baseline. The AUC was determined using the LOCF approach to impute missing values.
| total AUC (#ulcers*days) | Placebo (Oral) BID | Apremilast 30mg (Oral) BID |
|---|---|---|
| Area Under the Curve (AUC) for the Number of Oral Ulcers From Day 1 to 85 | 157.82 ± 12.890 | 67.74 ± 13.267 |
Area under curve (AUC\^85) from Day 1 to Day 85 for the number of genital ulcers per day was not analyzed.
No measurements were reported for this outcome.
Area under curve (AUC) from Day 1 to Day 85 (AUC\^85) for the number of oral plus genital ulcers per day was determined using the trapezoidal rule and divided by the days between the date of the last observation and baseline. The AUC was determined using the LOCF approach to impute missing values.
| total AUC (#ulcers*days) | Placebo (Oral) BID | Apremilast 30mg (Oral) BID |
|---|---|---|
| Area Under the Curve (AUC) for the Number of Oral Plus Genital Ulcers From Day 1 to 85 | 193.95 ± 161.492 | 65.79 ± 108.037 |
Sum of the number oral ulcers, genital ulcers or oral plus genital ulcers at Day 85
| Ulcers/participants | Placebo (Oral) BID | Apremilast 30mg (Oral) BID |
|---|---|---|
| Sum of the Number Oral Ulcers, Genital Ulcers or Oral Plus Genital Ulcers at Day 85 | 2.3 ± 0.35 | 0.6 ± 0.36 |
Comparison of the percentage of participants who were oral ulcer-free (complete response: free from active oral ulcers), or whose oral ulcers were reduced by ≥ 50%, (partial response) between the apremilast-treated and the placebo-treated groups. In this case, partial response also includes complete response.
| percentage of participants | Placebo (Oral) BID | Apremilast 30mg (Oral) BID |
|---|---|---|
| Complete Response | 28.6 | 70.9 |
| Partial Response | 50.0 | 89.1 |
The Behçet's Disease Current Activity Index consists of three component scores, a participant's perception of disease activity, a clinician's overall perception of disease activity and a Behçet's Disease Current Activity Index Score. The score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening) and a negative change from baseline indicates improvement.
| units on a scale | Placebo | Apremilast 30mg (Oral) BID |
|---|---|---|
| Change From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 85 | -0.1 ± 0.22 | -1.2 ± 0.22 |
A Treatment Emergent Adverse Event (TEAE) was defined as any AE occurring or worsening on or after the first treatment of any study drug, and within 28 days after the last dose of the last study drug. A treatment related toxicity was considered by the investigator to be not suspected or suspected. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE.
| participants | Placebo (Oral) BID | Apremilast 30mg (Oral) BID |
|---|---|---|
| Any TEAE | 50 | 49 |
| Any drug related TEAE | 24 | 30 |
| Any severe TEAE | 5 | 5 |
| Any serious TEAE | 3 | 2 |
| Any serious drug related TEAE | 1 | 0 |
| Any TEAE leading to drug interruption | 0 | 1 |
| Any TEAE leading to drug withdrawal | 5 | 4 |
A flare was defined as the development of new manifestations of BD or worsening of existing disease, meeting the following criteria: 1. Organ involvement: any major organ involvement (eg, central nervous system, gastrointestinal tract); 2. Oral/genital ulcers: ≥ 100% increase in the number of oral or genital ulcers from Day 1 or a minimum increase of 3 in the number of oral or genital ulcers, whichever is greater; 3. Arthritis: ≥ 50% increase in the number of swollen joints, or a minimum increase of 3 swollen joints, whichever is greater; 4. Skin lesions (non-oral/genital ulcers): ≥ 50% increase in the total score of the Physician's Global Assessment of Skin Lesions, or a minimum increase of 2 in the total score of the Physician's Global Assessment of Skin Lesions, whichever is greater' 5. New onset or worsening of existing Behçet Disease-related inflammatory eye disease requiring initiation of immunosuppressive therapy (uveitis).
| participants | Placebo (Oral) BID | Apremilast 30mg (Oral) BID |
|---|---|---|
| Participants who had disease flare | 27 | 12 |
| Participants with new onset or worsening uveitis | 3 | 0 |
The number of oral ulcers were counted at Day 169 in reference to the participants' first day of active treatment (Day 1 or Day 85).
| ulcers/participant | Placebo/Apremilast 30 mg | Apremilast 30 mg /Apremilast 30mg BID (Oral) |
|---|---|---|
| Number of Oral Ulcers at Day 169 | 0.4 ± 1.31 | 0.6 ± 1.27 |
A 100-mm VAS pain scale for oral ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
| units on a scale | Placebo/Apremilast 30 mg | Apremilast 30 mg /Apremilast 30mg BID (Oral) |
|---|---|---|
| Pain of Oral Ulcers as Measured by VAS (VAS Score) at Day 169 | 9.6 ± 21.13 | 9.7 ± 20.33 |
The percentage of participants who were genital ulcer-free (complete response: free from active genital ulcers)
| percentage of participants | Placebo/Apremilast 30 mg | Apremilast 30mg/Apremilast 30mg |
|---|---|---|
| Percentage of Participants Who Were Genital Ulcer-free (Complete Response) at Day 169 | 66.7 | 100 |
A 100-mm VAS pain scale for genital ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
No measurements were reported for this outcome.
The Behçet's Disease Current Activity Index consists of three component scores, a participant's perception of disease activity, a clinician's overall perception of disease activity and a Behçet's Disease Current Activity Index Score. The score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening) and a negative change from baseline indicates improvement.
| units on a scale | Placebo/Apremilast 30 mg | Apremilast 30mg/Apremilast 30mg |
|---|---|---|
| Behçet's Disease (BD) Current Activity Index Form Score at Day 169 | 1.4 ± 1.18 | 1.6 ± 1.62 |
A flare was defined as the development of new manifestations of BD or worsening of existing disease, meeting the following criteria: 1. Organ involvement: any major organ involvement (eg, central nervous system, gastrointestinal tract); 2. Oral/genital ulcers: ≥ 100% increase in the number of oral or genital ulcers from Day 1 or a minimum increase of 3 in the number of oral or genital ulcers, whichever is greater; 3. Arthritis: ≥ 50% increase in the number of swollen joints, or a minimum increase of 3 swollen joints, whichever is greater; 4. Skin lesions (non-oral/genital ulcers): ≥ 50% increase in the total score of the Physician's Global Assessment of Skin Lesions, or a minimum increase of 2 in the total score of the Physician's Global Assessment of Skin Lesions, whichever is greater; 5. New onset or worsening of existing Behçet Disease-related inflammatory eye disease requiring initiation of immunosuppressive therapy (uveitis).
| participants | Placebo/Apremilast 30 mg | Apremilast 30mg/Apremilast 30mg |
|---|---|---|
| Participants who experienced a disease flare | 15 | 19 |
| Participants with new onset or worsening uveitis | 1 | 2 |
The number of oral ulcers were counted at each visit and at the end of the treatment period (starting point was at baseline).
| ulcers/participants | Placebo/Apremilast 30 mg | Apremilast 30 mg /Apremilast 30mg BID (Oral) |
|---|---|---|
| Number of Oral Ulcers at Day 197 | 1.6 ± 1.78 | 1.7 ± 2.06 |
A 100-mm VAS pain scale for oral ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
| units on a scale | Placebo/Apremilast 30 mg | Apremilast 30 mg /Apremilast 30mg BID (Oral) |
|---|---|---|
| Pain of Oral Ulcers as Measured by VAS (VAS Score) at Day 197 | 21.0 ± 22.26 | 27.2 ± 28.71 |
The percentage of participants who were genital ulcer-free (complete response: free from active genital ulcers)
| percentage of participants | Placebo/Apremilast 30 mg | Apremilast 30mg/Apremilast 30mg |
|---|---|---|
| Percentage of Participants Who Were Genital Ulcer-free (Complete Response) | 100 | 100 |
A 100-mm VAS pain scale for genital ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
No measurements were reported for this outcome.
The Behçet's Disease Current Activity Index consists of three component scores, a participant's perception of disease activity, a clinician's overall perception of disease activity and a Behçet's Disease Current Activity Index Score. The score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening) and a negative change from baseline indicates improvement.
| units on a scale | Placebo/Apremilast 30 mg | Apremilast 30 mg/Apremilast 30mg BID |
|---|---|---|
| Change From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 197 | -0.6 ± 1.28 | -1.2 ± 1.65 |
A Treatment Emergent Adverse Event (TEAE) is as any AE occurring or worsening on or after the first treatment of any study drug, and within 28 days after the last dose of the last study drug. A treatment related toxicity was considered by the investigator to be not suspected or suspected. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE.
| particpants | Placebo BID/Apremilast 30 BID (Oral) | Apremilast 30 mg BID/Apremilast 30mg BID (Oral) |
|---|---|---|
| Any TEAE | 39 | 50 |
| Any drug related TEAE | 20 | 33 |
| Any severe TEAE | 1 | 11 |
| Any serious TEAE | 1 | 5 |
| Any serious drug related TEAE | 0 | 1 |
| TEAE leading to drug interuption | 0 | 1 |
| TEAE leading to drug withdrawal | 1 | 7 |
Collected over Days 1 to Day 197 visit; maximum exposure to study drug was 25.1 weeks. From Day 1 (first dose) through the end of the follow up period up to 28 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Week 12: Placebo BID | — | 3/56 (5.4%) | 48/56 (85.7%) |
| Week 12: Apremilast 30 mg BID | — | 2/55 (3.6%) | 47/55 (85.5%) |
| Week 24: Apremilast 30 mg BID | — | 6/100 (6%) | 82/100 (82%) |
| Event | Week 12: Placebo BID | Week 12: Apremilast 30 mg BID | Week 24: Apremilast 30 mg BID |
|---|---|---|---|
| Behçet's SyndromeImmune system disorders | 2/56 | 0/55 | 3/100 |
| DiplegiaNervous system disorders | 0/56 | 1/55 | 1/100 |
| Anal FissureGastrointestinal disorders | 0/56 | 1/55 | 1/100 |
| HaemorrhoidsGastrointestinal disorders | 0/56 | 1/55 | 1/100 |
| PyrexiaGastrointestinal disorders | 1/56 | 0/55 | 0/100 |
| InfluenzaInfections and infestations | 0/56 | 0/55 | 1/100 |
| Event | Week 12: Placebo BID | Week 12: Apremilast 30 mg BID | Week 24: Apremilast 30 mg BID |
|---|---|---|---|
| HeadacheNervous system disorders | 25/56 | 26/55 | 41/100 |
| Behçet's SyndromeImmune system disorders | 25/56 | 12/55 | 35/100 |
| NauseaGastrointestinal disorders | 10/56 | 22/55 | 36/100 |
| DiarrhoeaGastrointestinal disorders | 2/56 | 12/55 | 20/100 |
| VomitingGastrointestinal disorders | 1/56 | 9/55 | 12/100 |
| Abdominal PainGastrointestinal disorders | 7/56 | 8/55 | 11/100 |
| InfluenzaInfections and infestations | 1/56 | 3/55 | 13/100 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 5/56 | 6/55 | 13/100 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/56 | 3/55 | 11/100 |
| Decreased AppetiteMetabolism and nutrition disorders | 1/56 | 5/55 | 5/100 |
The intent to treat (ITT) population was defined as all randomized participants with at least one oral ulcer evaluation (including the baseline evaluation)
| Age, Continuous(years) | Placebo (Oral) BID | Apremilast 30mg (Oral) BID | Total |
|---|---|---|---|
| Mean | 34.7 ± 10.97 | 34.3 ± 9.11 | 34.5 ± 10.05 |
| Sex: Female, Male(Participants) | Placebo (Oral) BID | Apremilast 30mg (Oral) BID | Total |
|---|---|---|---|
| Female | 38 | 39 | 77 |
| Male | 18 | 16 | 34 |
| Duration of Behçet's disease(years) | Placebo (Oral) BID | Apremilast 30mg (Oral) BID | Total |
|---|---|---|---|
| Mean | 5.72 ± 6.084 | 4.92 ± 3.982 | 5.33 ± 5.143 |
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Aug 2009 to primary completion in May 2012, 33 months.
Results were first posted in Aug 2014, 2 years 3 months after primary completion. A results delay was requested in May 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast